Jamile M. Shammo

Hematology | Oncology

676 N St Clair St Ste 2140
Arkes Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Ravulizumab in pregnancy: the case for cautious optimism.

Ravulizumab in pregnancy: the case for cautious optimism.

Journal: Blood advances

Published: May 01, 2026

Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.

Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.

Journal: International journal of molecular sciences

Published: July 30, 2025

A prospective study of serum folate levels in patients with solid tumors treated with olaparib.

A prospective study of serum folate levels in patients with solid tumors treated with olaparib.

Journal: The oncologist

Published: May 09, 2025

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Journal: Hematology (Amsterdam, Netherlands)

Published: December 12, 2024

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Journal: Blood

Published: July 24, 2024

Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators.

Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators.

Journal: Therapeutic advances in hematology

Published: July 15, 2024

Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.

Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.

Journal: Blood reviews

Published: July 11, 2023

Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.

Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.

Journal: Blood advances

Published: May 06, 2022

Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.

Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.

Journal: Leukemia research

Published: April 28, 2022

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.

Journal: Journal of blood medicine

Published: February 22, 2022

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.

Journal: HemaSphere

Published: January 27, 2022

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis.

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis.

Journal: Case reports in oncology

Published: December 20, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026